as patients with insulin-treated iddm frequently experience problems with hypoglycaemia , and as amylin acts to modulate the action of insulin in various tissues , it is possible that amylin deficiency may contribute to morbidity in insulin-treated iddm , perhaps through the loss of a natural damping mechanism which guards against hypoglycaemia under conditions of normal physiology .
C0021641
insulin
C0011854
iddm